Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer155
Health Equity in Gynecologic Oncology: Focus on Limited English Proficiency116
Association between time to adjuvant chemotherapy and outcomes in low grade ovarian cancer83
What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy71
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results70
Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial69
Innovations in surgery and peri-operative care: A technical gimmick or true oncology advance?68
Platinum resistance: The great prognostic equalizer? Association between early disease characteristics and survival after diagnosis of platinum resistance in ovarian cancer67
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer66
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)64
Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis60
Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis59
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group58
CRABP2 – A novel biomarker for high-risk endometrial cancer56
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity54
A conceptual model of vulnerability to care delay among women at risk for endometrial cancer54
Impact of the 2023 FIGO staging on a high-risk endometrial cancer cohort52
Clinical characteristics of ovarian cancer patients with pathologic complete response after neoadjuvant chemotherapy51
Evaluating nutrition in advanced ovarian cancer: Which biomarker works best?49
Barriers faced by obstetrics and gynecology providers and trainees in providing HPV vaccination to patients aged 27–45 years48
Variables impacting postoperative length of stay for gynecologic cancer patients in the era of same day minimally invasive hysterectomy48
Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure45
Outcomes among patients with chronic kidney disease undergoing HIPEC for ovarian cancer42
The outcome of waiting for radiotherapy in locally advanced cervical cancer42
Economic burden of cervical cancer in Latin America: A real-world study42
Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with 41
Chemoradiotherapy response and the tumor microenvironment in a novel immunocompetent mouse model of cervical cancer41
Fertility-sparing surgery versus standard surgery for early-stage cervical cancer: Five-year life expectancies by tumor size41
Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial39
RE1 transcription factor is decreased in endometrial cancer38
Successful implementation of a goals-to-discharge patient checklist following surgery for gynecologic cancer38
Assessment of endocrine toxicities among gynecologic oncology patients receiving immunotherapy38
Factors associated with human papillomavirus vaccination: Determining the effect of implicit and explicit racial bias and state laws around vaccination37
A phase II, two-stage study of avelumab and axitinib among patients with mismatch repair proficient recurrent or persistent endometrial cancer: Final efficacy analysis and correlative studies36
A randomized controlled trial of wound infiltration with liposomal bupivacaine with or without intrathecal analgesia in patients undergoing laparotomy for advanced gynecologic malignancy36
Finding a needle in the haystack: Identifying risk of MDS/AML after PARP inhibitor treatment36
0.15034794807434